Developability Assessment

Our developability assessment service combines laboratory-based and in silico developability assessments to provide early insights into molecule characteristics and potential liabilities, optimize formulations, and mitigate risks. Coriolis Pharma offers cutting-edge developability assessment platform, tailored for modern biologics drug development challenges.
Designed and executed by our team of experts, it enables early decision-making and derisks the drug development process, ultimately saving time and money in later phases of development.

Empowering informed decisions quickly and efficiently in early stages

Conducting developability studies is an essential step in drug development that aims to identify the most promising drug candidates early on, before they enter more extensive clinical testing phases.

Coriolis Pharma’s developability assessments integrate both computational analyses and laboratory-based experiments to provide comprehensive support for clients and accelerate drug development timelines. By combining these approaches, the evaluation process becomes both more efficient and thorough.

While physical testing remains essential to validate predictions and confirm real-world behavior, the combined approach guides the identification of promising lead candidates, thus significantly reducing the number of molecules needing extensive experimental evaluation.

This developability assessment is further enhanced by a high-throughput preformulation screening platform that systematically explores various excipients and conditions tailored to antibody development. The data generated supports informed decision-making aligned with the quality target product profile (QTPP) of the therapeutic molecule, streamlining regulatory submissions and improving product predictability in real-world applications.

In Silico Developability Assessment

Coriolis Pharma’s developability platforms leverage in silico modeling to identify lead candidates with the highest success potential while defining formulation parameters. This method enables early detection of critical risks, including colloidal and conformational instability, aggregation, high viscosity, and chemical degradation pathways such as oxidation and deamidation—all without the need for physical material.

A standout feature of Coriolis Pharma’s multiscale approach is its ability to simulate molecular behavior across different timescales. Molecular dynamics models reveal detailed interactions within microseconds, whereas kinetic models forecast long-term stability over months or even years. This broad analytical scope helps evaluate candidate performance across diverse conditions and formulations.

By integrating computational predictions with experimental validation, Coriolis Pharma provides comprehensive and reliable stability assessments. This synergy ensures data-driven decision-making, customized formulation strategies, and more efficient development timelines.

mAbs Accelerator Platforms

Kick-start your program with our developability assessment and preformulation screening services. Leveraging our extensive scientific expertise, we’ve crafted these platforms to help you identify the optimal strategy from the outset and address potential stage-related risks.

We’ve worked with more than 930 compounds, and that number is growing by the day.

Preformulation Studies for Your Drug Product

We design preformulation studies for many biopharmaceutical drug products, including highly concentrated protein formulations and active pharmaceutical ingredients like live virus vaccines and viral vectors that fall under biosafety level 2.

Antibody or Related Product

Peptide

Therapeutic Protein

Gene & Cell Therapy

Viral Vector

Nucleic Acid

Vaccine

Nanoparticulate Delivery Systems

Your Phase

Coriolis designs preformulation studies to help you pick the best drug product candidate(s) and/or formulation design from the beginning of your program. This ultimately minimizes program failure risks, speeds up time to market and reduces costs.

Preclinical

Early Phase

Late Phase & Commercialization

Commercial Services

Coriolis Effect

See how our expertise and comprehensive services accelerate biologics development from preclinical to the market.